Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration
Sponsors
MoonLake Immunotherapeutics AG
Conditions
Psoriatic arthritishidradenitis suppurativa (HS)
Phase 3
A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneous sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (M1095-HS-301)
RecruitingCTIS2024-511360-87-00
Start: 2024-10-02Target: 262Updated: 2025-09-08
A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of subcutaneous sonelokimab in adult participants with moderate to severe hidradenitis suppurativa (M1095-HS-302)
Active, not recruitingCTIS2024-511363-28-00
Start: 2024-09-24Target: 292Updated: 2025-11-07
A Phase 3, parallel-group, randomized, double-blind, 3-arm, placebo-controlled, multicenter study to investigate the efficacy and safety of subcutaneous sonelokimab in male and female participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
RecruitingCTIS2024-516213-20-00
Start: 2025-03-25Target: 590Updated: 2025-10-17